Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production

Objective—The purpose of this study was to examine the effects of PPAR-&ggr; agonist rosiglitazone, relative to sulfonylureas, on circulating levels of adiponectin and the prothrombotic factor, plasminogen activator inhibitor (PAI)-1, in type 2 diabetic patients, and to investigate, in animal models, whether the antithrombotic action of rosiglitazone was mediated through adiponectin. Methods and Results—Our clinical study (n=64) showed that after 24-week add-on therapy, the rosiglitazone group had a greater mean reduction in plasma PAI-1 levels (25%, versus 12% in sulfonylurea group, P=0.002). Stepwise multiple linear regression analysis identified the reduction in plasma fasting glucose and the rise in adiponectin levels to be independently associated with the reduction in PAI-I concentration in the rosiglitazone-treated patients. Rosiglitazone (20 mg/kg/d) reduced adipose tissue PAI-1 mRNA expression and its plasma levels in wild-type C57 mice with diet-induced obesity (P<0.001), but this suppressive effect was attenuated in adiponectin knockout mice. Adenovirus-mediated overexpression of adiponectin led to a significant suppression of adipose tissue PAI-1 expression and its circulating concentrations in db/db diabetic mice. Our in vitro study demonstrated that recombinant adiponectin directly inhibited PAI-1 production in 3T3-L1 adipocytes. Conclusions—The antithrombotic effect of rosiglitazone is mediated, at least in part, through the suppressive effect of adiponectin on PAI-1 production.

[1]  Y. Aso,et al.  Comparison of the effects of pioglitazone and voglibose on circulating total and high‐molecular‐weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[2]  T. Lam,et al.  Hypoadiponectinemia as a Predictor for the Development of Hypertension: A 5-Year Prospective Study , 2007, Hypertension.

[3]  A. Bradbury,et al.  Obesity and thrombosis. , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[4]  P. Kern,et al.  Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. , 2006, American journal of physiology. Endocrinology and metabolism.

[5]  Kok Weng Chan,et al.  Post-translational Modifications of the Four Conserved Lysine Residues within the Collagenous Domain of Adiponectin Are Required for the Formation of Its High Molecular Weight Oligomeric Complex* , 2006, Journal of Biological Chemistry.

[6]  T. Noda,et al.  Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways* , 2006, Journal of Biological Chemistry.

[7]  A. Xu,et al.  Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. , 2006, Biochemical and biophysical research communications.

[8]  G. Lowe,et al.  Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke?: The Caerphilly Study , 2005, Circulation.

[9]  A. Xu,et al.  Adiponectin: Protection of the endothelium , 2005, Current diabetes reports.

[10]  R. Busse,et al.  Role of macrophage tissue infiltration in metabolic diseases , 2005, Current opinion in clinical nutrition and metabolic care.

[11]  R. Fogari,et al.  A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. , 2005, Diabetes research and clinical practice.

[12]  T. Funahashi,et al.  Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina , 2004, Thrombosis and Haemostasis.

[13]  C. Bode,et al.  Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones , 2004, Thrombosis and Haemostasis.

[14]  Kok Weng Chan,et al.  Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. , 2004, Endocrinology.

[15]  P. Grant,et al.  Beneficial effects of metformin on haemostasis and vascular function in man. , 2003, Diabetes & metabolism.

[16]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[17]  R. A. Norman,et al.  The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.

[18]  P. Saha,et al.  Increased β-Oxidation but No Insulin Resistance or Glucose Intolerance in Mice Lacking Adiponectin* , 2002, The Journal of Biological Chemistry.

[19]  D. Grobbee,et al.  Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. , 2002, Diabetes care.

[20]  P. Morange,et al.  Stromal Cells Are the Main Plasminogen Activator Inhibitor‐1‐Producing Cells in Human Fat: Evidence of Differences Between Visceral and Subcutaneous Deposits , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[21]  D. Dichek,et al.  Plasminogen Activator Inhibitor Type 1 Increases Neointima Formation in Balloon-Injured Rat Carotid Arteries , 2001, Circulation.

[22]  G. Pellegrini,et al.  Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[23]  W. Fay,et al.  Plasminogen Activator Inhibitor Type 1 Enhances Neointima Formation After Oxidative Vascular Injury in Atherosclerosis-Prone Mice , 2001, Circulation.

[24]  R. Westrick,et al.  Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. , 2000, Blood.

[25]  H. Hauner,et al.  Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[26]  K. Tsuchihashi,et al.  Troglitazone reduces plasma levels of tumour necrosis factor‐α in obese patients with type 2 diabetes , 2000, Diabetes, obesity & metabolism.

[27]  B. Sobel,et al.  Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. , 2000, Diabetes.

[28]  J. Corbett,et al.  Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. , 2000, Diabetes.

[29]  E. Ringelstein,et al.  Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology. , 1999, Neurological research.

[30]  L. Weinehall,et al.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. , 1998, Circulation.

[31]  B. Roussel,et al.  Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects. , 1998, Metabolism: clinical and experimental.

[32]  A. Evans,et al.  Associations of Fibrinogen, Factor VII and PAI-1 with Baseline Findings among 10,500 Male Participants in a Prospective Study of Myocardial Infarction , 1998, Thrombosis and Haemostasis.

[33]  B. Sobel,et al.  Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. , 1998, Circulation.

[34]  M. Blankenstein,et al.  The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. , 1993, Metabolism: clinical and experimental.

[35]  E. Cagliero,et al.  Increased Expression of Tissue Plasminogen Activator and Its Inhibitor and Reduced Fibrinolytic Potential of Human Endothelial Cells Cultured in Elevated Glucose , 1992, Diabetes.

[36]  P. Vague,et al.  Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. , 1987, Diabete & metabolisme.

[37]  F. Castellino,et al.  Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. , 2001, The American journal of pathology.